New & Notable
CDC Director fired as FDA restricts COVID-19 vaccine use
CDC Director Susan Monarez was fired the same day the FDA rescinded emergency use authorizations for COVID-19 vaccines, restricting use for seniors and high-risk younger people.
Lilly eyes FDA review after oral GLP-1 weight loss trial
Eli Lilly's daily oral GLP-1, orforglipron, led to weight loss and improved glycemic control in a Phase 3 trial, setting it up for FDA review and competition with oral Wegovy.
FDA begins publishing daily adverse drug reports for drugs, biologics
The FDA has begun releasing daily FAERS adverse event reports for all prescription drugs and biologics, enhancing post-market surveillance for frequent product monitoring.
U.S.-EU trade framework caps pharma tariffs on branded drugs at 15%
A new U.S.-EU trade framework caps pharma tariffs at 15% for branded pharmaceuticals and places generics and their ingredients under the "most-favored nation" rate system.
Insights
Insights is research conducted by and for TechTarget Xtelligent Healthcare. Our work aims to leverage Xtelligent’s diverse readership of healthcare professionals across various sectors of the industry to understand real-world challenges and identify effective solutions.
Access All Reports
Healthcare Strategies: A Podcast
-
A podcast for healthcare professionals seeking solutions to today's and tomorrow's top challenges. Hosted by the editors of Xtelligent Healthcare Media, this podcast series focuses on real-world use cases that are leading to tangible improvements in care quality, outcomes, and cost.
Guests from leading provider, payer, government, and other organizations share their approaches to transforming healthcare in a meaningful and lasting way.
View All Episodes
Latest News
-
Novo's $499 self-pay Ozempic bypasses payers, curbs compounders
Novo Nordisk's $499 self-pay program bypasses traditional payers to provide direct access to FDA-approved Ozempic and curb the uptake of unapproved compounded versions.
-
HHS restores defunct task force on childhood vaccine safety
HHS reinstates a defunct childhood vaccine safety task force following a lawsuit funded by Children's Health Defense, an anti-vaccine group previously led by HHS Secretary RFK Jr.
-
Studies link GLP-1 use to T2D rare eye risks, urge screening
New research links GLP-1 use in type 2 diabetes to slightly higher risks of optic neuropathy and diabetic retinopathy, with study authors urging regular preventative eye exams.
-
Trump's pharma import tariffs threaten drug pricing, generics
Trump's plan to raise pharma import tariffs up to 250% could drastically increase drug prices, eliminate access to affordable generics and limit R&D efforts across the industry.
-
HHS ends $500M in BARDA‑funded mRNA vaccine developments
With no announced timeline, HHS moves to terminate all mRNA vaccine development funded by BARDA, impacting 22 projects worth roughly $500 million.
-
FDA updates opioid pain medication labeling requirements
The FDA will soon require opioid makers to update safety labels to highlight the risks of addiction, misuse, overdose, high doses and long-term use.
Features
-
Using AI to identify, expose online drug counterfeiters
Pharmaceutical companies are leveraging AI's advanced detection and enforcement tools to combat the online counterfeit drug market, protecting brand integrity and consumer safety.
-
Exploring Red No. 3 ban reformulation strategies for Rx, OTC drugs
By Jan. 15, 2028, drug makers must rethink their approach to excipients, stability and color strategy to remove Red No. 3 from ingested prescription and over-the-counter products.
-
Understanding the importance of randomized clinical trials
Randomized controlled trials are the gold standard for proving therapeutic value, drug safety and efficacy, shaping pricing, reimbursement and securing regulatory approval.
-
How oral GLP-1 drugs could disrupt the weight loss market
FDA-approved oral GLP-1 formulations for weight loss could disrupt the weight management market, outcompete injectables and reduce patient access barriers.